New details of how the president has demanded faster action from health agencies help explain the intensifying concern that he could demand pre-Election Day approval of a vaccine.
A ruined economy and a broken health care system have left President Nicolás Maduro unable to fight the pandemic as other world leaders have. Instead, he’s detained thousands to try to halt the spread.
The goal of the initiative is admirable: getting a coronavirus vaccine out to Americans and saving lives as soon as possible. It is not, however, without its problems.
How much freedom should front-line clinicians have in treating Covid-19 patients with unproven drugs? The question opened up a civil war in some hospitals.
The world’s largest vaccine producer, the Serum Institute, announced a plan to make hundreds of millions of doses of an unproven inoculation. It’s a gamble with a huge upside. And huge risks.
Well-timed stock bets have generated big profits for senior executives and board members at companies developing vaccines and treatments.
A weighted lottery gives everyone a chance at a drug or vaccine in short supply. But some have a better shot than others.
A small study of an inhaled form of a commonly available drug, interferon beta, suggested it could reduce the odds of patients becoming severely ill.
Confronted by illnesses that most scientists overlook, these families had to work out their own approaches to find treatments.
By some measures, it is winning the race, with four companies already testing their vaccine candidates on humans.
As scientists at the Jenner Institute prepare for mass clinical trials, new tests show their vaccine to be effective in monkeys.
The drug, sarilumab, sold as Kevzara, didn’t show benefits to patients who were hospitalized but not on ventilators. The study will continue with critically ill patients.